Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/β-catenin pathway cross-talk and suppress medulloblastoma growth (Cancer Research (2010) 70, (266-76) DOI: 10.1158/0008-5472.CAN-09-0578);Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/β-catenin pathway cross-talk and suppress medulloblastoma growth

Cancer Research

Volumn 70, Issue 1, 2010, Pages 266-276

  Baryawno, Ninib ^a   Sveinbjörnsson, Baldur ^a,b   Eksborg, Staffan ^a   Chen, Ching Shih ^c   Kogner, Per ^a   Johnsen, John Inge ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; BETA CATENIN; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; VINCRISTINE; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MEDULLOBLASTOMA; MITOCHONDRION; MOUSE; NONHUMAN; ONCOGENE C MYC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; XENOGRAFT;

EID: 75149180021     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0036     Document Type: Erratum

References (49)

1. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008;14:135-45.
2. Schuller U, Heine VM, Mao J, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008;14:123-34.
3. Hambardzumyan D, Becher OJ, Holland EC. Cancer stem cells and survival pathways. Cell Cycle 2008;7:1371-8.
4. Ille F, Sommer L. Wnt signaling: multiple functions in neural development. Cell Mol Life Sci 2005;62:1100-8.
5. Fodde R, Brabletz T. Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007;19:150-8.
6. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
7. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
8. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92.
9. Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 2006;12:3019-27.
10. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
11. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008;22:436-48.
12. Johnsen JI, Kogner P, Albihn A, Henriksson MA. Embryonal neural tumours and cell death. Apoptosis 2009;14:424-38.
13. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
14. Baryawno N, Sveinbjornsson B, Eksborg S, et al. Tumorgrowth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro-oncol 2008;10:661-74.
15. Johnsen JI, Segerstrom L, Orrego A, et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008.
16. Johnsen JI, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 2004;64:7210-5.
17. Ponthan F, Wickstrom M, Gleissman H, et al. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 2007; 13:1036-44.
18. Zhu J, Huang JW, Tseng PH, et al. From the cyclooxygenase-2 in-hibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-18.
19. Rao G, Pedone CA, Valle LD, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 2004;23:6156-62.
20. Del Valle L,Wang JY, Lassak A, et al. Insulin-like growth factor I receptor signaling system in JC virus T antigen-induced primitive neuroectodermal tumors-medulloblastomas. J Neurovirol 2002;8Suppl 2:138-47.
21. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-76.
22. Wlodarski PK, Boszczyk A, Grajkowska W, Roszkowski M, Jozwiak J. Implication of active Erk in the classic type of human medulloblastoma. Folia Neuropathol 2008;46:117-22.
23. Urbanska K, Trojanek J, Del Valle L, et al. Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3β constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene 2007;26:2308-17.
24. Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003;35:197-8.
25. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52.
26. Washiyama K, Muragaki Y, Rorke LB, et al. Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system. Am J Pathol 1996;148:929-40.
27. Barbero S, Bajetto A, Bonavia R, et al. Expression of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 in human brain tumors and their involvement in glial proliferation in vitro. Ann N Y Acad Sci 2002;973:60-9.
28. Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 2004;10:7613-20.
29. Chilton-Macneill S, Ho M, Hawkins C, Gassas A, Zielenska M, Baruchel S. C-kit expression and mutational analysis in medulloblastoma. Pediatr Dev Pathol 2004;7:493-8.
30. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27: 5511-26.
31. Lawlor MA, Mora A, Ashby PR, et al. Essential role of PDK1 in regulating cell size and development in mice. EMBO J 2002;21: 3728-38.
32. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 in-hibitors. J Natl Cancer Inst 2006;98:736-47.
33. Johnson AJ, Smith LL, Zhu J, et al. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 2005;105:2504-9.
34. Yacoub A, Park MA, Hanna D, et al. OSU-03012 promotes caspaseindependent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006;70:589-603.
35. Zhang S, Suvannasankha A, Crean CD, et al. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 2007;13:4750-8.
36. Gao M, Yeh PY, Lu YS, et al. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res 2008;68:9348-57.
37. Nogueira V, Park Y, Chen CC, et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008; 14:458-70.
38. Guerreiro AS, Fattet S, Fischer B, et al. Targeting the PI3K p110α isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 2008;14:6761-9.
39. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007;25: 4806-12.
40. Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61:1527-32.
41. Baeza N, Masuoka J, Kleihues P, Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003;22:632-6.
42. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of β-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000; 59:333-7.
43. Huang H, Mahler-Araujo BM, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000;156:433-7.
44. Ellison DW, Onilude OE, Lindsey JC, et al. β-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005;23:7951-7.
45. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, et al. Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation. Oncogene 2001;20:252-9.
46. Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell 2003;4:499-515.
47. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L. IGF-II induces rapid β-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001;20:4942-50.
48. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51. 49. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004;5:209-18.
49. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006;25:329-37.